May 8 (Reuters) - McKesson MCK.N forecast fiscal 2026 profit largely above estimates on Thursday and said it is planning to spin off its medical-surgical solutions unit into an independent company to focus on its core drug distribution business.
Shares of the drug distributor rose 2% in extended trading.
The company said separation of the unit, which supplies surgical instruments and services, will allow it to focus on distribution of cancer drugs and other specialty medicines, which have shown higher growth and provide better margins.
Drug distributors in the United States are expanding their presence in the market for specialty medicines, which treat complex conditions such as cancer and rheumatoid arthritis, due to their high profit margins.
Texas-headquartered McKesson expects per-share profit in the range of $36.75 to $37.55 for fiscal 2026, compared with analysts' average estimate of $36.76, according to data compiled by LSEG.
The company reported fourth-quarter revenue of $90.8 billion, missing analysts' average estimate of $94.3 billion.
On an adjusted basis, McKesson earned $10.12 per share, compared with the estimates of $9.82 per share.
The drug distributor's U.S. pharmaceutical unit — its largest segment by revenue — recorded sales of $83.2 billion. That was 21% higher than the year earlier, driven by sales of cancer drugs, but missed analysts' estimate of $85.8 billion.
(Reporting by Christy Santhosh in Bengaluru; Editing by Leroy Leo)
((Christy.Santhosh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。